Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015681 | 1.00 | KMT2A (0.37) | KMT2ATRPV1CHRNB4CHRNA3HTT | |
| SCHEMBL5128792 | 0.92 | KMT2A (0.37) | KMT2ATRPV1SMN1; SMN2 | |
| SCHEMBL5130510 | 0.89 | KMT2A (0.42) | KMT2ATRPV1CHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL5015680 | 0.86 | CHRNB4 (0.35) | KMT2ACHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL5116128 | 0.82 | RAB9A (0.54) | KMT2ATRPV1SMN1; SMN2POLB | |
| SCHEMBL5119948 | 0.80 | KMT2A (0.38) | KMT2ATRPV1SMN1; SMN2 | |
| SCHEMBL5012873 | 0.80 | MEN1 (0.51) | KMT2AHTTSMN1; SMN2POLB | |
| SCHEMBL5012896 | 0.80 | MAPT (0.45) | KMT2A | |
| SCHEMBL5129522 | 0.79 | KMT2A (0.41) | KMT2ATRPV1CHRNB4CHRNA3SMN1; SMN2 | |
| SCHEMBL16175483 | 0.79 | RAB9A (0.37) | KMT2ACHRNB4CHRNA3HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | KMT2A 4006/4885TRPV1 57/4885CHRNB4 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.